Opinion of the Transparency Council – Treatment of mucopolysaccharidosis type II (Hunter syndrome) (ICD-10 E76.1)
At its meeting on 3 February 2025, the Transparency Council adopted opinion No. 19/2025 on the introduction of changes to the B.25 drug program “Treatment of mucopolysaccharidosis type II (Hunter syndrome) (ICD-10 E76.1)”